BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. 2004

Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Winship Cancer Institute and Department of Chemistry, Emory University, Atlanta, GA 30322, USA.

A series of novel curcumin analogs were synthesized and screened for anti-cancer and anti-angiogenesis activities at Emory University and at the National Cancer Institute (NCI). These compounds are symmetrical alpha,beta-unsaturated and saturated ketones. The majority of the analogs demonstrated a moderate degree of anti-cancer activity. Compounds 10, 11, and 14 exhibited a high degree of cytotoxicity in the NCI in vitro anti-cancer cell line screen. In addition, this screen revealed that these compounds inhibit tumor cell growth with a higher potency than the commonly used chemotherapeutic drug, cisplatin. In independent in vitro screens conducted at Emory, the same compounds plus 4, 5, 8, 9, and 13 exhibited a high degree of cytotoxicity to tumor cells. Analogs that were effective in the anti-cancer screens were also effective in in vitro anti-angiogenesis assays. Compounds 4, 9, 11, and 14 were most effective in the anti-angiogenesis assays run at Emory. In the assays conducted by the NCI, compound 14 was almost as potent as the anti-angiogenic drug TNP-470, which has undergone clinical trials. Based on the favorable in vitro anti-cancer and anti-angiogenesis results with 14, further in vivo tests were conducted. This compound effectively reduced the size of human breast tumors grown in female athymic nude mice and showed little toxicity. This data, coupled with the remarkable in vitro data, suggests that compound 14 may potentially be an effective chemotherapeutic agent. As a follow-up, a 3D quantitative structure relationship based on 14 has been developed. It shows a cross-validated r2(q2) and a predictive r2(p2) = 0.71. COMPARE analysis suggests the compound to be a possible RNA/DNA antimetabolite, but also implies that the compound's cytotoxicity may arise from a presently unknown mechanism.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D003474 Curcumin A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-,Curcumin Phytosome,Diferuloylmethane,Mervia,Turmeric Yellow,Phytosome, Curcumin,Yellow, Turmeric
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D020533 Angiogenesis Inhibitors Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. Angiogenesis Factor Inhibitor,Angiogenesis Inhibitor,Angiogenetic Antagonist,Angiogenetic Inhibitor,Angiogenic Antagonist,Angiogenic Antagonists,Angiogenic Inhibitor,Angiostatic Agent,Angiostatic Agents,Anti-Angiogenetic Agent,Anti-Angiogenic Drug,Anti-Angiogenic Drugs,Antiangiogenic Agent,Neovascularization Inhibitor,Neovascularization Inhibitors,Angiogenesis Factor Inhibitors,Angiogenetic Antagonists,Angiogenetic Inhibitors,Angiogenic Inhibitors,Antagonists, Angiogenic,Anti-Angiogenesis Effect,Anti-Angiogenesis Effects,Anti-Angiogenetic Agents,Antiangiogenesis Effect,Antiangiogenesis Effects,Antiangiogenic Agents,Inhibitors, Angiogenesis,Inhibitors, Angiogenetic,Inhibitors, Angiogenic,Inhibitors, Neovascularization,Agent, Angiostatic,Agent, Anti-Angiogenetic,Agent, Antiangiogenic,Agents, Angiostatic,Agents, Anti-Angiogenetic,Agents, Antiangiogenic,Antagonist, Angiogenetic,Antagonist, Angiogenic,Antagonists, Angiogenetic,Anti Angiogenesis Effect,Anti Angiogenesis Effects,Anti Angiogenetic Agent,Anti Angiogenetic Agents,Anti Angiogenic Drug,Anti Angiogenic Drugs,Drug, Anti-Angiogenic,Drugs, Anti-Angiogenic,Effect, Anti-Angiogenesis,Effect, Antiangiogenesis,Effects, Anti-Angiogenesis,Effects, Antiangiogenesis,Factor Inhibitor, Angiogenesis,Factor Inhibitors, Angiogenesis,Inhibitor, Angiogenesis,Inhibitor, Angiogenesis Factor,Inhibitor, Angiogenetic,Inhibitor, Angiogenic,Inhibitor, Neovascularization,Inhibitors, Angiogenesis Factor
D021241 Spectrometry, Mass, Electrospray Ionization A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. ESI Mass Spectrometry,Electrospray Ionization Mass Spectrometry,Mass Spectrometry, ESI,Spectrometry, ESI Mass
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents.
March 2014, European journal of medicinal chemistry,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of asymmetric indole curcumin analogs as potential anti-inflammatory and antioxidant agents.
February 2014, Journal of enzyme inhibition and medicinal chemistry,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of curcumin analogs as β-amyloid imaging agents.
September 2017, Future medicinal chemistry,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.
March 2015, Bioorganic & medicinal chemistry letters,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents.
March 2014, European journal of medicinal chemistry,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.
January 2014, Journal of Asian natural products research,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of novel bavachinin analogs as anticancer agents.
February 2018, European journal of medicinal chemistry,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents.
May 2017, Bioorganic & medicinal chemistry letters,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and Cytotoxic Evaluation of Monocarbonyl Analogs of Curcumin as Potential Anti-Tumor Agents.
February 2016, Drug development research,
Brian K Adams, and Eva M Ferstl, and Matthew C Davis, and Marike Herold, and Serdar Kurtkaya, and Richard F Camalier, and Melinda G Hollingshead, and Gurmeet Kaur, and Edward A Sausville, and Frederick R Rickles, and James P Snyder, and Dennis C Liotta, and Mamoru Shoji
Synthesis and biological evaluation of imidamide analogs as selective anti-trypanosomal agents.
May 2022, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!